AngioDynamics ANGO Med Tech — Gross Profit
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AngioDynamics in its filing.
Tagged under the XBRL concept us-gaap:GrossProfit.
The official record: AngioDynamics’s 10-Q, filed April 2, 2026, on SEC EDGAR. View the filing →
Ask your AI about AngioDynamics's med tech — gross profit.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AngioDynamics's med tech — gross profit?
- AngioDynamics (ANGO) reported med tech — gross profit of $23.29M in Q4 2025.
- How has AngioDynamics's med tech — gross profit changed year-over-year?
- AngioDynamics's med tech — gross profit increased by 18.9% year-over-year, from $19.59M to $23.29M.
- What is the long-term trend for AngioDynamics's med tech — gross profit?
- Over 4 years (2021 to 2025), AngioDynamics's med tech — gross profit has grown at a 18.7% compound annual growth rate (CAGR), from $39.54M to $78.52M.
- What does med tech — gross profit mean?
- Gross profit for the Med Tech segment is calculated as net sales minus the direct costs of production and delivery. It serves as a primary indicator of the segment's ability to generate value from its core medical device offerings after covering manufacturing expenses. This metric is critical for evaluating the segment's fundamental profitability and pricing power in the competitive medical technology market.